



Supplementary Figure 1. The number of patients without concurrent intravenous alteplase treatment with 90-day mRS scores 0–2 in the nerinetide (NA1) and control arms per individual ASPECTS category. Note that although the ESCAPE-NA1 trial mandated a baseline ASPECTS >5 for enrollment, some patients with baseline ASPECTS <5 were still enrolled based on ASPECTS assessment at the local sites that differed from the core lab assessment that was performed centrally (protocol violations). ASPECTS scores shown in the figure are core-lab adjudicated ASPECTS scores read by experienced core lab members. ASPECTS, Alberta Stroke Program Early CT Score; mRS, modified Rankin Scale.